Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial–

Read more at globenewswire.com